MAAT INDEX

CLAIM #58673 · UnitedHealth Group Incorporated (UNH) · 2023Q4 earnings call · Jan 12, 2024 · due Dec 31, 2024

within Medicare Advantage, we expect a majority of our full-year growth outlook to be realized outside the annual enrollment period with the growth patterns consistent with those we have experienced over the more recent years.

John Rex · CFO

PENDING
graded after results covering Dec 31, 2024 are reported

In context

rease of $2.1 billion over last year. This growth was driven by our diverse and expanding product portfolio, which connects many of the key stakeholders across healthcare, whether it's launching new decision support solutions for providers, claims editing software for payers, or simplifying the payment process for all, our continued investments are fostering the next phase of Optum Insight growth. Optum Rx revenues grew 16% to over $116 billion, driven by the continued addition of new clients, expansion with an existing relationship, and organic growth of our pharmacy services businesses. In 2023, both customer retention and new wins were among the best Optum Rx has delivered. At UnitedHealthcare full-year revenues of over $281 billion grew nearly 13%. Adding to Andrew's earlier comments, within Medicare Advantage, we expect a majority of our full-year growth outlook to be realized outside the annual enrollment period with the growth patterns consistent with those we have experienced over the more recent years. Our Medicaid enrollment outlook for 2024 balances two key elements. First is that, state redetermination activities will be largely completed by mid-year. And second, that growth within existing states such as North Carolina and other new opportunities will partially offset these impacts. Within our domestic commercial offerings, we expect to serve about 1.5 million additional people in ‘24, a strong result. And we are encouraged by the continued positive customer response we are experiencing as we look ahead. Our ample capital capacities continue to underpin our long-term growth objectives. Cash flow from operations in ‘23 was $29 billion or 1.3 times net income. We returned nearly $15 billion to shareholders through share repurchase and dividends and deployed over $10 billion in growth

Verify independently

SEC filings for UNH · Claim quote is verbatim from the 2023Q4 earnings call.